Related Experiment Video
Updated: Jan 1, 2026
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Research progress on the relationship between lung cancer drug-resistance and microRNAs
Xuan Ma1, Ai-Ling Liang1, Yong-Jun Liu1
1Medical Molecular Diagnostics Key Laboratory of Guangdong & Departments of Biochemistry and Molecular Biology & Departments of Clinical Biochemistry, Guangdong Medical University, 523808, Dongguan, Guangdong, P.R. China.
Abstract:
Lung cancer, a malignant tumor with the highest death rate of cancer, seriously endangers human health. And its pathogenesis and mechanism of drug resistance has been partially clarified, especially for the signal pathway of epidermal growth factor receptor (EGFR). The targeting therapy of EGFR signaling pathway in non-small cell lung cancer (NSCLC) has achieved a certain effect, but the two mutation of EGFR and other mechanisms of lung cancer resistance still greatly reduce the therapeutic effect of chemotherapy on it. MicroRNA is an endogenous non coding RNA, which has a regulatory function after transcriptional level. Recent studies on the mechanism of lung cancer resistance have found that a variety of microRNAs are related to the mechanism of lung cancer drug-resistance. They can regulate lung cancer resistance by participating in signal pathways, drug resistance genes and cell apoptosis, thus affecting the sensitivity of cancer cells to drugs. Therefore, microRNAs can be used as a specific target for the treatment of lung cancer and plays a vital role in the early diagnosis, prognosis and treatment of lung cancer. This article reviews the mechanisms of lung cancer resistance and its relationship with microRNAs.
Insights
MicroRNAs regulate drug resistance in lung cancer by affecting signaling pathways and apoptosis. Understanding these microRNAs is crucial for developing new lung cancer treatments and improving patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Lung cancer is a leading cause of cancer-related mortality, with drug resistance significantly limiting treatment efficacy.
- Epidermal growth factor receptor (EGFR) signaling pathway targeting has shown promise in non-small cell lung cancer (NSCLC), but resistance mechanisms persist.
- MicroRNAs (non-coding RNAs) are increasingly recognized for their regulatory roles in biological processes, including cancer drug resistance.
Purpose of the Study:
- To review the mechanisms of lung cancer drug resistance.
- To explore the relationship between microRNAs and lung cancer drug resistance.
- To highlight the potential of microRNAs as therapeutic targets and diagnostic markers for lung cancer.
Main Methods:
- Literature review of studies on lung cancer pathogenesis and drug resistance mechanisms.
- Analysis of research on the role of microRNAs in regulating cancer cell sensitivity to chemotherapy.
- Synthesis of information on microRNA involvement in signaling pathways, drug resistance genes, and apoptosis.
Main Results:
- MicroRNAs are implicated in various lung cancer drug resistance mechanisms.
- They can modulate sensitivity to chemotherapy by influencing key cellular processes.
- Specific microRNAs have been identified as potential regulators of drug resistance in lung cancer.
Conclusions:
- MicroRNAs play a significant role in the development and progression of lung cancer drug resistance.
- Targeting microRNAs offers a promising strategy for overcoming drug resistance and enhancing lung cancer therapy.
- MicroRNAs hold potential as biomarkers for early diagnosis, prognosis, and personalized treatment of lung cancer.
More Related Videos
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs
02:56Treatment Resistant Cancers